Gustav Ullenhag

Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma

Ejder, Patric; Jespersen, Henrik; Hernberg, Micaela; Ny, Lars et al.

Part of BMC Cancer, 2026

• DOI for Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma
• Download full text (pdf) of Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma

Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients

Grauers Wiktorin, Hanna; Rydén, Viktoria; Ek, Ida; Eriksson, Emma et al.

Part of Biomarker Research, 2026

• DOI for Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients
• Download full text (pdf) of Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients

Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study

Helgadottir, Hildur; Ny, Lars; Ullenhag, Gustav; Mikiver, Rasmus et al.

Part of European Journal of Cancer, 2026

• DOI for Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study
• Download full text (pdf) of Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer

Ladjevardi, Cecilia Olsson; Skribek, Marcus; Koliadi, Anthoula; Rydén, Viktoria et al.

Part of Cancer Immunology and Immunotherapy, 2025

• DOI for Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
• Download full text (pdf) of Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer

Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB-C and III cutaneous malignant melanoma (TRIM): an interim analysis of a multicentre, randomised, phase 3 trial in Sweden

O. Ladjevardi, Cecilia; Naeser, Ylva; Dyrke, Ulf; Papantoniou, Dimitrios et al.

Part of The Lancet Oncology, p. 1501-1510, 2025

• DOI for Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB-C and III cutaneous malignant melanoma (TRIM): an interim analysis of a multicentre, randomised, phase 3 trial in Sweden

Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma

Ejder, Patric; Jespersen, Henrik; Hernberg, Micaela; Ny, Lars et al.

Part of BMC Cancer, 2026

• DOI for Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma
• Download full text (pdf) of Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma

Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients

Grauers Wiktorin, Hanna; Rydén, Viktoria; Ek, Ida; Eriksson, Emma et al.

Part of Biomarker Research, 2026

• DOI for Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients
• Download full text (pdf) of Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients

Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study

Helgadottir, Hildur; Ny, Lars; Ullenhag, Gustav; Mikiver, Rasmus et al.

Part of European Journal of Cancer, 2026

• DOI for Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study
• Download full text (pdf) of Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer

Ladjevardi, Cecilia Olsson; Skribek, Marcus; Koliadi, Anthoula; Rydén, Viktoria et al.

Part of Cancer Immunology and Immunotherapy, 2025

• DOI for Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
• Download full text (pdf) of Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer

Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB-C and III cutaneous malignant melanoma (TRIM): an interim analysis of a multicentre, randomised, phase 3 trial in Sweden

O. Ladjevardi, Cecilia; Naeser, Ylva; Dyrke, Ulf; Papantoniou, Dimitrios et al.

Part of The Lancet Oncology, p. 1501-1510, 2025

• DOI for Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB-C and III cutaneous malignant melanoma (TRIM): an interim analysis of a multicentre, randomised, phase 3 trial in Sweden

Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement

Fletcher, Erika A. K.; Cordfunke, Robert A.; Nasi, Aikaterini; Törnqvist, Gunilla et al.

Part of Molecular Therapy Oncology, 2025

• DOI for Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement
• Download full text (pdf) of Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement

Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab

Kheir, Alaa; Johannsdottir, Berglind; Gronn-Weiss, Alexandra; Liu, Lisa L. et al.

Part of Acta Oncologica, p. 1355-1364, 2025

• DOI for Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab
• Download full text (pdf) of Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab

Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma: A Swedish retrospective real-world study (NEO-MEL)

Nelson, Axel; Krabbe, Ellen; Björkström, Karl; Huibers, Anne et al.

Part of European Journal of Cancer, 2025

• DOI for Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma: A Swedish retrospective real-world study (NEO-MEL)
• Download full text (pdf) of Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma: A Swedish retrospective real-world study (NEO-MEL)

Survival and Quality of Life After Isolated Hepatic Perfusion With Melphalan as a Treatment for Uveal Melanoma Liver Metastases: Final Results From the Phase III Randomized Controlled Trial SCANDIUM

Olofsson Bagge, Roger; Nelson, Axel; Shafazand, Amir; All-Eriksson, Charlotta et al.

Part of Annals of Surgery, p. 100-107, 2025

• DOI for Survival and Quality of Life After Isolated Hepatic Perfusion With Melphalan as a Treatment for Uveal Melanoma Liver Metastases: Final Results From the Phase III Randomized Controlled Trial SCANDIUM
• Download full text (pdf) of Survival and Quality of Life After Isolated Hepatic Perfusion With Melphalan as a Treatment for Uveal Melanoma Liver Metastases: Final Results From the Phase III Randomized Controlled Trial SCANDIUM

First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies

Carneiro, Ana; Hahn, Amanda; Ellmark, Peter; Enell Smith, Karin et al.

Part of Journal for ImmunoTherapy of Cancer, 2025

• DOI for First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies
• Download full text (pdf) of First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies

Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness

Ladjevardi, Cecilia Olsson; Koliadi, Anthoula; Rydén, Viktoria; El-Naggar, Ali Inan et al.

Part of Frontiers in Oncology, 2024

• DOI for Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
• Download full text (pdf) of Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness

CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling

Naseri, Sedigheh; Mejia Cordova, Mariela; Wenthe, Jessica; Lövgren, Tanja et al.

Part of Journal of Cellular and Molecular Medicine, 2024

• DOI for CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling
• Download full text (pdf) of CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling

A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial)

Bagge, R. Olofsson; Nelson, A.; Shafazand, A.; Cahlin, C. et al.

Part of ESMO Open, 2024

• DOI for A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial)
• Download full text (pdf) of A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial)

Risk factors for the increasing incidence of pregnancy-associated cancer in Sweden: a population-based study

Lundberg, Frida E.; Stensheim, Hanne; Ullenhag, Gustav; Sahlgren, Hanna Milerad et al.

Part of Acta Obstetricia et Gynecologica Scandinavica, p. 669-683, 2024

• DOI for Risk factors for the increasing incidence of pregnancy-associated cancer in Sweden: a population-based study
• Download full text (pdf) of Risk factors for the increasing incidence of pregnancy-associated cancer in Sweden: a population-based study

The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis

Rydén, Viktoria; El-Naggar, Ali Inan; Koliadi, Anthoula; Ladjevardi, Cecilia Olsson et al.

Part of Pigment Cell & Melanoma Research, 2024

• DOI for The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
• Download full text (pdf) of The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis

LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001) results from arm 1 of a non-randomised, single-centre, phase 1/2 study

Musher, Benjamin L.; Rowinsky, Eric K.; Smaglo, Brandon G.; Abidi, Wasif et al.

Part of The Lancet Oncology, p. 488-500, 2024

• DOI for LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001) results from arm 1 of a non-randomised, single-centre, phase 1/2 study

Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study

Ladjevardi, Cecilia Olsson; Koliadi, Anthoula; Rydén, Viktoria; Inan El-Naggar, Ali et al.

Part of Cancer Medicine, p. 13217-13224, 2023

• DOI for Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study
• Download full text (pdf) of Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study

Survival in patients diagnosed with melanoma in situ compared to the general population. A Swedish population-based matched cohort study

Naeser, Ylva; Mikiver, Rasmus; Ingvar, Christian; Lambe, Mats et al.

Part of eClinicalMedicine, 2023

• DOI for Survival in patients diagnosed with melanoma in situ compared to the general population. A Swedish population-based matched cohort study
• Download full text (pdf) of Survival in patients diagnosed with melanoma in situ compared to the general population. A Swedish population-based matched cohort study

Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models

Wenthe, Jessica; Eriksson, Emma; Hellström, Ann-Charlotte; Moreno, Rafael et al.

Part of Journal of Translational Medicine, 2023

• DOI for Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models
• Download full text (pdf) of Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models

Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study

Helgadottir, Hildur; Ny, Lars; Ullenhag, Gustav; Falkenius, Johan et al.

Part of Journal of the National Cancer Institute, p. 1077-1084, 2023

• DOI for Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study
• Download full text (pdf) of Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study

Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy

Sah, Vasu R.; Jespersen, Henrik; Karlsson, Joakim; Nilsson, Lisa M. et al.

Part of Cancer Research Communications, p. 884-895, 2023

• DOI for Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy
• Download full text (pdf) of Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy

Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial)

Olofsson Bagge, Roger; Nelson, Axel; Shafazand, Amir; All-Eriksson, Charlotta et al.

Part of Journal of Clinical Oncology, p. 3042-3050, 2023

• DOI for Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial)

Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study)

Naeser, Ylva; Helgadottir, Hildur; Hansson, Johan; Ingvar, Christian et al.

Part of Cancers, 2022

• DOI for Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study)
• Download full text (pdf) of Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study)

Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition

Wenthe, Jessica; Naseri, Sedigheh; Hellström, Ann-Charlotte; Moreno, Rafael et al.

Part of MOLECULAR THERAPY-ONCOLYTICS, p. 429-442, 2022

• DOI for Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition
• Download full text (pdf) of Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition

Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial

Backlund, Ellen; Yang, Muyi; Grozman, Vitali; Masucci, Giuseppe et al.

Part of Acta Oncologica, p. 869-873, 2022

• DOI for Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial

Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer

Elfving, Hedvig; Broström, Erika; Moens, Lotte N.J.; Almlöf, Jonas et al.

Part of Lung Cancer, p. 53-59, 2021

• DOI for Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer

A case report of a patient with metastatic uveal melanoma who experienced a complete response to treatment with the NIVO3+IPI1 regimen

Schiza, Aglaia; Naeser, Ylva; Sundin, Anders; Ullenhag, Gustav

Part of Clinical Oncology: Case Reports, 2021

Socioeconomy as a prognostic factor for location of death in Swedish palliative cancer patients

Nilsson, Jonas; Holgersson, Georg; Ullenhag, Gustav; Holmgren, Malin et al.

Part of BMC Palliative Care, 2021

• DOI for Socioeconomy as a prognostic factor for location of death in Swedish palliative cancer patients
• Download full text (pdf) of Socioeconomy as a prognostic factor for location of death in Swedish palliative cancer patients

Surgery of metastatic melanoma after systemic therapy - the SUMMIST trial: study protocol for a randomized controlled trial

Holmberg, Carl Jacob; Katsarelias, Dimitrios; Jespersen, Henrik; Carneiro, Ana et al.

Part of Acta Oncologica, p. 52-55, 2021

• DOI for Surgery of metastatic melanoma after systemic therapy - the SUMMIST trial: study protocol for a randomized controlled trial

Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors

Valachis, Antonios; Rosén, Camilla; Koliadi, Anthoula; Digkas, Evangelos et al.

Part of Oncoimmunology, 2021

• DOI for Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors
• Download full text (pdf) of Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors

Cancer survival in women diagnosed with pregnancy-associated cancer: An overview using nationwide registry data in Sweden 1970-2018

Johansson, Anna L.; Fredriksson, Irma; Mellemkjaer, Lene; Stensheim, Hanne et al.

Part of European Journal of Cancer, p. 106-115, 2021

• DOI for Cancer survival in women diagnosed with pregnancy-associated cancer: An overview using nationwide registry data in Sweden 1970-2018
• Download full text (pdf) of Cancer survival in women diagnosed with pregnancy-associated cancer: An overview using nationwide registry data in Sweden 1970-2018

Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients

Eltahir, mohmo394; Fletcher, E.; Dynesius, L.; Jarblad, J. L. et al.

Part of International Immunopharmacology, 2021

• DOI for Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients
• Download full text (pdf) of Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients

Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors.

Irenaeus, Sandra; Hellström, Vivan; Wenthe, Jessica; Krause, Johan et al.

Part of Cancer Gene Therapy, p. 1188-1197, 2021

• DOI for Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors.

TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma

Naeser, Ylva; Helgadottir, Hildur; Brandberg, Yvonne; Hansson, Johan et al.

Part of BMC Cancer, 2020

• DOI for TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma
• Download full text (pdf) of TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma

Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib

Niinivirta, Marjut; Georganaki, Maria; Enblad, Gunilla; Lindskog, Cecilia et al.

Part of BMC Cancer, 2020

• DOI for Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib
• Download full text (pdf) of Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.

Tholander, Bengt; Koliadi, Anthoula; Botling, Johan; Dahlstrand, Hanna et al.

Part of Upsala Journal of Medical Sciences, p. 325-329, 2020

• DOI for Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.

European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatment

Derksen, Jeroen W. G.; Warren, Graham W.; Jordan, Karin; Rauh, Stefan et al.

Part of European Journal of Cancer, p. 99-108, 2020

• DOI for European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatment
• Download full text (pdf) of European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatment

Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination

Lövgren, Tanja; Wolodarski, Maria; Wickstrom, Stina; Edback, Ulrika et al.

Part of Oncoimmunology, 2020

• DOI for Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination
• Download full text (pdf) of Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination

Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients

Schiza, Aglaia; Irenaeus, Sandra; Ortiz-Nieto, Francisco; Loskog, Angelica S. et al.

Part of Scientific Reports, 2019

• DOI for Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients
• Download full text (pdf) of Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients

Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study

Jespersen, Henrik; Bagge, Roger Olofsson; Ullenhag, Gustav; Carneiro, Ana et al.

Part of BMC Cancer, 2019

• DOI for Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study
• Download full text (pdf) of Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study

Tumoral pyruvate kinase L/R as a predictive marker for the treatment of renal cancer patients with sunitinib and sorafenib

Niinivirta, Marjut; Enblad, Gunilla; Lindskog, Cecilia; Pontén, Fredrik et al.

Part of Journal of Cancer, p. 3224-3231, 2019

• DOI for Tumoral pyruvate kinase L/R as a predictive marker for the treatment of renal cancer patients with sunitinib and sorafenib
• Download full text (pdf) of Tumoral pyruvate kinase L/R as a predictive marker for the treatment of renal cancer patients with sunitinib and sorafenib

First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies

Irenaeus, Sandra; Nielsen, Dorte; Ellmark, Peter; Yachnin, Jeffrey et al.

Part of International Journal of Cancer, p. 1189-1199, 2019

• DOI for First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies

Cancer treatment of today in view of the Nobel Prize

Ullenhag, Gustav

Part of Upsala Journal of Medical Sciences, p. 205-206, 2018

• DOI for Cancer treatment of today in view of the Nobel Prize
• Download full text (pdf) of Cancer treatment of today in view of the Nobel Prize

A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma

Gremel, Gabriela; Djureinovic, Dijana; Niinivirta, Marjut; Laird, Alexander et al.

Part of BMC Cancer, 2017

• DOI for A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma
• Download full text (pdf) of A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma

Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Schiza, Aglaia; Wenthe, Jessica; Mangsbo, Sara; Svensson, Emma et al.

Part of Journal of Translational Medicine, 2017

• DOI for Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients
• Download full text (pdf) of Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients

Irenaeus, Sandra; Schiza, Aglaia; Mangsbo, Sara M.; Wenthe, Jessica et al.

Part of Oncotarget, p. 78573-78587, 2017

• DOI for Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients
• Download full text (pdf) of Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients

Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients

Niinivirta, Marjut; Enblad, Gunilla; Edqvist, Per-Henrik D; Pontén, Fredrik et al.

Part of Journal of Cancer, p. 3975-3983, 2017

• DOI for Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients
• Download full text (pdf) of Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients

Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.

Svensson, Emma; Milenova, Ioanna; Wenthe, Jessica; Ståhle, Magnus et al.

Part of Clinical Cancer Research, p. 5846-5857, 2017

• DOI for Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.

Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer

Ullenhag, Gustav J.; Mozaffari, Fariba; Broberg, Mats; Mellstedt, Hakan et al.

Part of PLOS ONE, 2017

• DOI for Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
• Download full text (pdf) of Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer

Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib

Niinivirta, Marjut; Enblad, Gunilla; Edqvist, Per-Henrik; Pontén, Fredrik et al.

Part of Journal of Cancer Research and Clinical Oncology, p. 961-970, 2017

• DOI for Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib
• Download full text (pdf) of Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib

Adenovirus-mediated CD40L gene transfer increases teffector/tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Schiza, Aglaia; Wenthe, Jessica; Mangsbo, Sara; Eriksson, Emma et al.

Part of Scandinavian Journal of Immunology, p. 337-337, 2017

Activating CD40 While Inhibiting IL6R Induces Cytokine Production without PDL1 Upregulation in DCs

Eriksson, Emma; Milenova, Ioanna; Wenthe, Jessica; Moreno, Rafael et al.

Part of Molecular Therapy, p. 54-54, 2017

Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment

Eriksson, Emma; Moreno, R; Milenova, I. Yoanna; Liljenfeldt, L et al.

Part of Gene Therapy, p. 92-103, 2017

• DOI for Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment
• Download full text (pdf) of Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment

A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib

Maleka, Aglaia; Åström, Gunnar; Bystrom, P.; Ullenhag, Gustav J.

Part of BMC Cancer, 2016

• DOI for A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib
• Download full text (pdf) of A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib

Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer

Eriksson, Emma; Wenthe, Jessica; Irenaeus, Sandra; Loskog, Angelica et al.

Part of Journal of Translational Medicine, 2016

• DOI for Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer
• Download full text (pdf) of Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer

Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay

Blokzijl, Andries; Chen, Lei; Gustafsdottir, Sigrun M.; Vuu, Jimmy et al.

Part of PLOS ONE, 2016

• DOI for Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay
• Download full text (pdf) of Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay

Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

Loskog, Angelica; Maleka, Aglaia; Mangsbo, Sara; Svensson, Emma et al.

Part of British Journal of Cancer, p. 872-880, 2016

• DOI for Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer

Ullenhag, Gustav J.; Rossmann, Eva; Liljefors, Maria

Part of PLOS ONE, 2015

• DOI for A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
• Download full text (pdf) of A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer

The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis

Ullenhag, Gustav J.; Al-Attar, Ahmad; Mukherjee, Abhik; Green, Andrew R. et al.

Part of Journal of Cancer Research and Clinical Oncology, p. 505-514, 2015

• DOI for The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis

Trends in cutaneous malignant melanoma in Sweden 1997-2011: thinner tumours and improved survival among men

Lyth, J.; Eriksson, H.; Hansson, J.; Ingvar, C. et al.

Part of British Journal of Dermatology, p. 700-706, 2015

• DOI for Trends in cutaneous malignant melanoma in Sweden 1997-2011: thinner tumours and improved survival among men

Immunomodulatory effects of lenalidomide in combination with gemcitabine as first-line treatment in patients with advanced pancreatic cancer

Liljefors, Maria; Mozaffari, F. S.; Mellstedt, H.; Ullenhag, Gustav

Part of Annals of Oncology, p. 12-12, 2015

Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial

Olofsson, Roger; Ny, Lars; All-Ericsson, Charlotta; Eilard, Malin Sternby et al.

Part of Trials, 2014

• DOI for Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial
• Download full text (pdf) of Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial

AdCD40L Immunostimulatory Gene Therapy in Combination with Cyclophosphamide Prolongs 6-Months Survival in a Phase I/II Trial for Malignant Melanoma

Loskog, Angelica; Maleka, Aglaia; Mangsbo, Sara; Svensson, Emma et al.

Part of Molecular Therapy, 2014

• DOI for AdCD40L Immunostimulatory Gene Therapy in Combination with Cyclophosphamide Prolongs 6-Months Survival in a Phase I/II Trial for Malignant Melanoma

Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study

Schadendorf, D.; Amonkar, M. M.; Milhem, M.; Grotzinger, K. et al.

Part of Annals of Oncology, p. 700-706, 2014

• DOI for Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study

Mortality in women with pregnancy-associated malignant melanoma

Johansson, Anna L. V.; Andersson, Therese M-L.; Plym, Anna; Ullenhag, Gustav J. et al.

Part of The Journal of American Academy of Dermatology, p. 1093-1101, 2014

• DOI for Mortality in women with pregnancy-associated malignant melanoma

Rapid expansion of T cells: Effects of culture and cryopreservation and importance of short-term cell recovery

Sadeghi, Arian; Ullenhag, Gustav; Wagenius, Gunnar; Tötterman, Thomas H et al.

Part of Acta Oncologica, p. 978-986, 2013

• DOI for Rapid expansion of T cells: Effects of culture and cryopreservation and importance of short-term cell recovery

Treatment of Metastatic Malignant Melanoma With Vemurafenib During Pregnancy

Maleka, Aglaia; Enblad, Gunilla; Sjörs, Gunnar; Lindqvist, Anna et al.

Part of Journal of Clinical Oncology, 2013

• DOI for Treatment of Metastatic Malignant Melanoma With Vemurafenib During Pregnancy

Whole-body MRI including diffusion-weighted imaging compared to CT for staging of malignant melanoma

Mosavi, Firas; Ullenhag, Gustav; Ahlström, Håkan

Part of Upsala Journal of Medical Sciences, p. 91-97, 2013

• DOI for Whole-body MRI including diffusion-weighted imaging compared to CT for staging of malignant melanoma

AdCD40L immunostimulatory gene therapy shifts the MDSC- and macrophage profiles and promotes T cell infiltration in the tumor microenvironment

Liljenfeldt, Lina; Svensson, E.; Huang, H.; Dieterich, L. et al.

Part of Human Gene Therapy, 2013

Treatment of metastatic malignant melanoma with vemurafenib during pregnancy

Maleka, Aglaia; Enblad, Gunilla; Sjörs, Gunnar; Lindqvist, Anna et al.

Part of Journal of Clinical Oncology, 2013

• DOI for Treatment of metastatic malignant melanoma with vemurafenib during pregnancy
• Download full text (pdf) of Treatment of metastatic malignant melanoma with vemurafenib during pregnancy

Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy

Ullenhag, Gustav J; Sadeghi, Arian M; Carlsson, Björn; Ahlström, Håkan et al.

Part of Cancer Immunology and Immunotherapy, p. 725-732, 2012

• DOI for Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy

Response to the letter to the editors from Inge Marie Svane on our manuscript "Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy"

Wagenius, Gunnar; Ullenhag, Gustav J.; Tötterman, Thomas H.

Part of Cancer Immunology and Immunotherapy, p. 749-749, 2012

• DOI for Response to the letter to the editors from Inge Marie Svane on our manuscript "Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy"

Induction of IgM, IgA and IgE Antibodies in Colorectal Cancer Patients Vaccinated with a Recombinant CEA Protein

Staff, Caroline; Magnusson, Carl G. M.; Hojjat-Farsangi, Mohammad; Mosolits, Szilvia et al.

Part of Journal of Clinical Immunology, p. 855-865, 2012

• DOI for Induction of IgM, IgA and IgE Antibodies in Colorectal Cancer Patients Vaccinated with a Recombinant CEA Protein

Serological and immunohistochemical analysis of S100 and derivatives as markers for prognosis of newly operated malignant melanoma patients

Bolander, Åsa; Agnarsdóttir, Margrét; Wagenius, Gunnar; Strömberg, Sara et al.

Part of Melanoma research, p. 412-419, 2008

• DOI for Serological and immunohistochemical analysis of S100 and derivatives as markers for prognosis of newly operated malignant melanoma patients

The Role of Circulating Angiogenic Factors in Patients Operated on for Localized Malignant Melanoma

Bolander, Åsa; Wagenius, Gunnar; Larsson, Anders; Brattström, Daniel et al.

Part of Anticancer Research, p. 3211-3217, 2007

Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.

Liljefors, Maria; Ragnhammar, Peter; Nilsson, Bo; Ullenhag, Gustav et al.

Part of Int J Oncol, p. 703-11, 2004

Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis

Valachis, Antonis; Ullenhag, Gustav

Part of European Journal of Cancer, p. 106-115, 2017

• DOI for Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis

AdCD40L: Crossing the Valley of Death?

Ullenhag, Gustav; Loskog, Angelica S I

Part of International Reviews of Immunology, p. 289-298, 2012

• DOI for AdCD40L: Crossing the Valley of Death?

Safety of intratumoral immunostimulatory LOAd703 gene therapy in patients with advanced cancer

Irenaeus, Sandra; Wenthe, Jessica; Eriksson, Emma; Schiza, Aglaia et al.

Immunological evaluation of immunostimulatory gene therapy targeting CD40/4-1BB in advanced cancer patients (LOKON002)

Wenthe, Jessica; Eriksson, Emma; Naseri, Sedigheh; Sandin, Linda et al.

Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models

Wenthe, Jessica; Eriksson, Emma; Hellström, Ann-Charlotte; Moreno, Rafael et al.

LOAd703 Gene Engineering Induces Tumor Cell Immunogenicity and Enhances the Effect of Chemotherapy in Ovarian Cancer Models

Naseri, Sedigheh; Härdin, Jonas; Mejia Cordova, Mariela; Eriksson, Emma et al.